CYP2D6*41与*9或*10携带者中O/N-去甲文拉法辛代谢比的显著差异:基于1003例斯堪的纳维亚患者治疗药物监测数据的研究
本研究基于挪威奥斯陆治疗药物监测服务中1003例(主要为高加索人)的CYP2D6基因型与文拉法辛及其代谢物血清浓度数据,以O-去甲/ N-去甲文拉法辛代谢比(MR)作为CYP2D6生物标志物,比较CYP2D6*9-10(合并)与CYP2D6*41携带者的CYP2D6代谢功能。结果显示CYP2D6*41携带者的MR显著低于CYP2D6*9-10携带者(P < 0.002),且CYP2D6*41/null携带者中86.7%的MR落在CYP2D6null/null携带者观察范围内,而CYP2D6*9-10/null携带者仅17.4%。基于多元线性回归估计,CYP2D6*41的活性评分为0.095,CYP2D6*9-10为0.34,提示应区分这些等位基因以准确从基因型推断CYP2D6表型。
要点
- CYP2D6*41携带者的O/N-去甲文拉法辛代谢比显著低于CYP2D6*9-10携带者(P < 0.002)。
- CYP2D6*41/null携带者中86.7%的MR落在CYP2D6null/null携带者范围内。
- 计算活性评分:CYP2D6*41为0.095,CYP2D6*9-10为0.34,提示应区分这些等位基因。
核心结论
- 以O/N-去甲文拉法辛代谢比衡量的CYP2D6代谢在CYP2D6*41携带者中显著低于CYP2D6*9-10携带者。
- 从基因型分类CYP2D6表型时应区分CYP2D6*41与CYP2D6*9-10。
研究设计与样本
- 研究纳入来自挪威奥斯陆治疗药物监测服务的1003例患者(主要为高加索人),具有CYP2D6基因型和文拉法辛及其代谢物血清浓度数据。
- 以O-去甲/ N-去甲文拉法辛代谢比(MR)作为CYP2D6生物标志物,采用Mann-Whitney检验比较CYP2D6*9-10(合并)与CYP2D6*41携带者(与CYP2D6*1或非编码null等位基因组合)。
- 通过多元线性回归获得MR亚组估计值以计算CYP2D6*9-10和CYP2D6*41活性评分。
主要发现
- CYP2D6*41携带者的MR显著低于CYP2D6*9-10携带者(P < 0.002)。
- CYP2D6*41/null携带者中86.7%的MR落在CYP2D6null/null携带者的观察范围内,而CYP2D6*9-10/null携带者中仅17.4%。
- 多元分析中CYP2D6基因型解释了MR变异的60.7%。
- 亚组MR估计值:CYP2D6*1/null(n = 269)为9.54(95% CI 7.45-12.20),CYP2D6*9-10/null(n = 17)为3.55(2.06-6.10),CYP2D6*41/null(n = 30)为1.33(0.87-2.05),CYP2D6null/null(n = 95)为0.47(0.35-0.61)。
- 基于这些估计,CYP2D6*41的计算活性评分为0.095,CYP2D6*9-10为0.34。
关键数值与推荐
- CYP2D6*41与CYP2D6*9-10的MR比较P < 0.002。
- CYP2D6*41/null与CYP2D6*9-10/null携带者MR落在CYP2D6null/null范围内的比例分别为86.7%和17.4%。
- 亚组MR估计值:CYP2D6*1/null 9.54(95% CI 7.45-12.20),CYP2D6*9-10/null 3.55(2.06-6.10),CYP2D6*41/null 1.33(0.87-2.05),CYP2D6null/null 0.47(0.35-0.61)。
- CYP2D6*41活性评分为0.095,CYP2D6*9-10为0.34。
临床怎么用
- 在根据CYP2D6基因型推断表型时,应将CYP2D6*41与CYP2D6*9-10区分开来,避免将CYP2D6*41携带者误判为与CYP2D6*9-10相同的中间代谢表型。
- 对于携带CYP2D6*41/null基因型的患者,其CYP2D6代谢功能可能接近null/null携带者,临床用药时应考虑更低的CYP2D6活性。
- 本研究结果基于文拉法辛的代谢比,外推到其他CYP2D6底物时需谨慎。
局限性
- 研究样本主要来自斯堪的纳维亚高加索人群,结果外推到其他种族人群需谨慎。
- MR作为CYP2D6生物标志物基于文拉法辛及其代谢物,可能不完全代表其他CYP2D6底物的代谢。
- 部分亚组样本量较小(如CYP2D6*9-10/null n = 17),估计值可能存在不确定性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: CYP2D6*9, CYP2D6*10 and CYP2D6*41 are the most frequent reduced-function CYP2D6 alleles in Caucasians. Despite lacking in vivo evidence, they are collectively classified with an enzyme activity score of 0.5. Thus, the aim of this study was to compare the functional impact of CYP2D6*9, CYP2D6*10 and CYP2D6*41 on CYP2D6 metabolism in a large patient population. METHODS: A total of 1003 patients (mainly Caucasians) with data on CYP2D6 genotype and serum concentrations of venlafaxine and metabolites were included from a therapeutic drug monitoring service in Oslo, Norway. The O-desmethyl-to-N-desmethyl-venlafaxine metabolic ratio (MR) was applied as CYP2D6 biomarker and compared (Mann-Whitney) between carriers of CYP2D6*9-10 (merged) and CYP2D6*41, either combined with CYP2D6*1 or non-coding (null) alleles. MR subgroup estimates were obtained by multiple linear regression for calculations of CYP2D6*9-10 and CYP2D6*41 activity scores. RESULTS: MR was significantly lower in carriers of CYP2D6*41 than CYP2D6*9-10 (P < 0.002). The majority of CYP2D6*41/null carriers (86.7%) had MR in the observed range of CYP2D6null/null carriers compared with the minority of CYP2D6*9-10/null carriers (17.4%). CYP2D6 genotype explained 60.7% of MR variability in the multivariate analysis providing subgroup estimates of 9.54 (95% CI; 7.45-12.20), 3.55 (2.06-6.10), 1.33 (0.87-2.05) and 0.47 (0.35-0.61) in carriers of CYP2D6*1/null (n = 269), CYP2D6*9-10/null (n = 17), CYP2D6*41/null (n = 30) and CYP2D6null/null (n = 95), respectively. Based on these estimates, the calculated activity score of CYP2D6*41 was 0.095 compared to 0.34 for CYP2D6*9-10. CONCLUSIONS: CYP2D6 metabolism measured as the O/N-desmethylvenlafaxine ratio is significantly lower in Scandinavian carriers of CYP2D6*41 vs. CYP2D6*9-10. Thus, these alleles should be differentiated when classifying CYP2D6 phenotype from genotype.
引用
- Haslemo T, Eliasson E, Jukić MM, et al. Significantly lower CYP2D6 metabolism measured as the O/N-desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients. Br J Clin Pharmacol. 2018. PMID: 30312494. doi:10.1111/bcp.13788
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。